ArticlePhysiological reports2025
Neuroprotective effect of cedrol in a male rat model of Parkinson's disease.
Article in Physiological reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Dapagliflozin ameliorates motor deficits in a Parkinson's disease model induced by 6-OHDA: An integrative in vivo and in silico approach from α-synuclein/A2AAR/TH/TNF-α to APAF-1/caspase-3 modulation.Inflammopharmacology · 2026Article
- Metabolites associated with endophytic fungi in agarwood: fungal compounds and host metabolites triggered by fungi.Mycology · 2026Review
- GC-MS Profiling, Antioxidant, Enzyme Inhibition, Molecular Docking, and ADME Investigation of the n-Hexane Extract and the Essential Oil of Platycladus orientalis (L.) Franco Fruits.Chemistry & biodiversity · 2026Article
- Advances in Naturally and Synthetically Derived Bioactive Sesquiterpenes and Their Derivatives: Applications in Targeting Cancer and Neurodegenerative Diseases.Molecules (Basel, Switzerland) · 2025Review
- Neuroprotective effect of cedrol in a male rat model of Parkinson's disease.Physiological reports · 2025Article
- Effects of inhalingFrontiers in psychology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cedrol is a natural sesquiterpene subgroup of terpenes with antioxidant and anti-inflammatory properties. This study evaluated the effect of cedrol on the 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease (PD). Unilateral injection of 6-OHDA was performed to induce the PD model. Cedrol at 10 mg/kg and 20 mg/kg was administrated. The rotarod test, apomorphine-induced rotational test, and open field tests assessed motor function, while the passive avoidance test was used to evaluate cognitive function. Furthermore, striatal levels of malondialdehyde (MDA) and total thiol, and SOD (superoxide dismutase) activity were measured. The induction of lesion led to a significantly higher number of rotations in the apomorphine-induced rotational test, lower maintenance in the rotarod test, as well as a shorter delay for entering into and a longer duration of time spent in the dark chamber in the passive avoidance test, versus the control group. It also enhanced the striatal levels of MDA and diminished the striatal SOD activity and level of total thiol. Administration of cedrol significantly improved behavioral tests and biochemical assays. Cedrol could benefit cognitive and motor functions in a rat model of PD. Its antioxidant properties might mediate these effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.